EyeGene Inc. (KOSDAQ:185490)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,035.00
+40.00 (1.34%)
Last updated: Jun 27, 2025
14.53%
Market Cap 83.66B
Revenue (ttm) 3.65B
Net Income (ttm) -12.00B
Shares Out 27.03M
EPS (ttm) -443.42
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 33,167
Average Volume 62,815
Open 2,995.00
Previous Close 2,995.00
Day's Range 2,985.00 - 3,080.00
52-Week Range 2,460.00 - 4,720.00
Beta 1.49
RSI 43.12
Earnings Date Aug 13, 2025

About EyeGene

EyeGene Inc. engages in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea. Its product pipeline comprises EG-Mirotin, which has completed Phase 2a clinical trial to treat diabetic retinopathy; EG-Decorin which completed Phase 2 clinical trial for the treatment of pressure ulcers and wound healing; and EG-Myocin, which has completed Phase II clinical trials for the treatment of myocardial ischemia/reperfusion injury. It also develops EG-HZ, which has completed phase 1 ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2000
Employees 49
Stock Exchange KOSDAQ
Ticker Symbol 185490
Full Company Profile

Financial Performance

In 2024, EyeGene's revenue was 3.36 billion, an increase of 7.37% compared to the previous year's 3.13 billion. Losses were -12.13 billion, -42.54% less than in 2023.

Financial Statements

News

There is no news available yet.